araag2/HINT huggingface dataset:
Clinical trial NCT02732119 (phase 1/phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ribociclib, everolimus, exemestane
SMILES: CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Adult men and women

          -  Patient has a confirmed diagnosis of estrogen-receptor positive and/or progesterone
             receptor positive breast cancer by local laboratory and has HER2-negative breast
             cancer

          -  Patient must have either measurable disease by RECIST 1.1 or bone lesions in absence
             of measurable disease.

          -  ECOG Performance Status 0 - 1

          -  Disease refractory to either, AI, tamoxifen or fulvestrant

          -  Previously treated on any CDK 4/6 inhibitor.

          -  Patient has adequate bone marrow and organ function.

        Exclusion Criteria:

          -  Patient with symptomatic visceral disease or any disease burden that makes the patient
             ineligible for endocrine therapy per the investigator's best judgment.

          -  Patient has received more than one line of chemotherapy for advanced disease.

          -  Previous treatment with mTOR inhibitors, or exemestane for advanced disease.

          -  Progressed on more than one CDK 4/6 inhibitor

          -  Patient with CNS involvement unless they are at least 4 weeks from prior therapy
             completion.

          -  Clinically significant, uncontrolled heart disease and/or recent cardiac events.
Clinical trial NCT02739906 (phase 1/phase 2, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: biochaperone human insulin (hinsbet®), insulin lispro (humalog®), regular human insulin (huminsulin® normal)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subject aged 18-64 years (both inclusive).

          -  Type 1 diabetes mellitus (as diagnosed clinically) >= 12 months.

          -  Treated with multiple daily insulin injections or CSII >= 12 months.

          -  Current total daily insulin treatment < 1.2 (I)U/kg/day.

          -  Current total daily bolus insulin treatment < 0.7 (I)U/kg/day.

          -  BMI 18.5-28.0 kg/m^2 (both inclusive).

          -  HbA1c <= 9.0 % by local laboratory analysis

          -  Fasting C-peptide <= 0.30 nmol/L.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to IMPs or related products.

          -  Type 2 diabetes mellitus.

          -  Previous participation in this trial. Participation is defined as randomised.

          -  Participation in any clinical trial within 3 months prior to this trial.

          -  Clinically significant abnormal haematology, coagulation, biochemistry, lipids, or
             urinalysis screening tests, as judged by the Investigator considering the underlying
             disease.

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea), as judged by the Investigator.

          -  Known slowing of gastric emptying and or gastrointestinal surgery that in the opinion
             of the Investigator might change gastrointestinal motility and food absorption.

          -  Unusual meal habits and special diet requirements or unwillingness to eat the food
             provided in the trial.

          -  Females of childbearing potential who are pregnant, breast-feeding or intend to become
             pregnant or are not using highly effective contraceptive methods
Clinical trial NCT02740712 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: caffeine, warfarin, omeprazole, midazolam, digoxin, vitamin k, rucaparib
SMILES: CN1C=NC2=C1C(=O)N(C)C(=O)N2C, S1SSSSSSS1, [Na+].OC([O-])=O, CC1=CC(O)=CC(C)=C1Cl, OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O, CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced solid tumor

          -  Have evidence of measurable disease as defined by RECIST Version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate bone marrow, renal, and liver function

        Exclusion Criteria:

          -  Prior treatment with chemotherapy, radiation, antibody therapy or other immunotherapy,
             gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs within
             14 days prior to Day 1

          -  Prior treatment with any poly adenosine diphosphate ribose polymerase inhibitor
             (PARPi)

          -  Arterial or venous thrombi (including cerebrovascular accident), myocardial
             infarction, admission for unstable angina, cardiac angioplasty, stenting or poorly
             controlled hypertension within the last 3 months prior to Screening;

          -  Pre-existing duodenal stent, recent or existing bowel obstruction, and/or any
             gastrointestinal disorder or defect that would, in the opinion of the Investigator,
             interfere with absorption of study drugs

          -  Current use of therapeutic anticoagulation (low molecular weight heparin, oral
             anticoagulant agents including acetylsalicylic acid),

          -  Current use of one of the probe drugs;

          -  Untreated or symptomatic central nervous system (CNS) metastases.

          -  Evidence or history of bleeding disorder

          -  Participation in another investigational drug trial within 30 days prior to Day 1 (or
             5 times the half-life of the drug, whichever is longer) or exposure to more than three
             new investigational agents within 12 months prior to Day 1;

          -  Acute illness within 14 days prior to Day 1 unless mild in severity and approved by
             the Investigator and Sponsor's medical representative

          -  Active second malignancy, i.e., patient known to have potentially fatal cancer present
             for which they may be (but not necessarily) currently receiving treatment.
Clinical trial NCT02743546 (phase 1, status: withdrawn)
Conditions: leukemia, lymphocytic, chronic, b-cell, lymphoma, large b-cell, diffuse, lymphoma, follicular, lymphoma, mantle-cell
ICD codes: C91.11, C91.12, C91.10, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: duvortuxizumab, ibrutinib
SMILES: NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  The participant has a B-cell malignancy (diffuse large B-cell lymphoma [DLBCL],
             follicular lymphoma [FL], mantle cell lymphoma [MCL], or chronic lymphocytic leukemia
             [CLL]) with tumor progression following at least one (MCL and CLL) or two (DLBCL and
             FL) prior standard therapies

          -  The participant has a radiographically measurable tumor that requires treatment
             according to the treating physician

          -  The participant is able to carry out daily life activities with significant difficulty

          -  The participant has adequate organ and blood cell counts

          -  Sexually active participants must use medically acceptable methods of contraception
             during the course of the study

        Exclusion Criteria:

          -  The participant has a brain tumor or significant side effects, including severe
             neurological side effects, from a previous anti-cancer treatment

          -  Current severe, uncontrolled systemic disease including an ongoing, active infection
             or history of clinically significant heart problems

          -  History of autoimmune disease, allogeneic hematopoietic stem cell transplant, or organ
             transplant

          -  The participant has received any of the following: ibrutinib or other Bruton's
             tyrosine kinase (BTK) inhibitor at any time; an agent targeting CD19-positive cells or
             CD3-expressing T cells at any time; or warfarin, a vitamin K antagonist, or a blood
             transfusion (red blood cells and/or platelets) within 1 week of starting the study

          -  The participant is pregnant, breastfeeding, or planning to become pregnant or father a
             child
Clinical trial NCT02751385 (phase 1, status: terminated)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: microgynon, nintedanib
SMILES: COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1
Reason stopped: 
    terminated- study halted due to low recruitment.
  
Eligibility criteria:

        Inclusion criteria:

          -  Female patients 18 years or older at screening

          -  Female patient is postmenopausal or surgically sterilised

          -  Patient with locally advanced, metastatic or locally recurrent non-small cell lung
             cancer with histology of adenocarcinoma

          -  Nintedanib (Vargatef®) is planned to be prescribed in accordance with the marketing
             authorisation (SmPC)

          -  Signed and dated written informed consent in accordance with Good Clinical Practice
             (GCP) and local legislation prior to admission to the trial

        Exclusion criteria:

          -  Any contraindication to nintedanib (Vargatef®), ethinylestradiol or levonorgestrel
             (Microgynon®), as specified in the respective labels

          -  Use of hormone containing contraceptives (including vaginal and intrauterine devices
             and including hormone replacement therapy) within 30 days prior to first
             administration of Microgynon®

          -  Systemic use of drugs known to induce (e.g. rifampicin, St. John's Wort,
             carbamazepine) or to inhibit (e.g. azole antimycotics, macrolides) CYP3A4 within 7
             days prior to first trial drug administration until last pharmacokinetic(PK)-sampling
             in the trial. Exception: allowed is the intake of corticosteroids as docetaxel
             (pre)medication

          -  History of major thrombotic or clinically relevant major bleeding event in the past 6
             months

          -  Persistence of clinically relevant therapy related toxicities (i.e. > Common
             Terminology Criteria for Adverse Events [CTCAE] grade 2) from previous chemotherapy
             and/or radiotherapy

          -  Treatment with other investigational drugs or treatment in another clinical trial
             within the past four weeks before start of therapy or concomitantly with this trial

          -  Gastrointestinal disorders or abnormalities that would interfere with absorption of
             the trial drugs

          -  Major surgery (major according to the investigator's assessment) performed within 4
             weeks prior to first treatment within the trial and without complete wound healing

          -  Patients who must or wish to continue the intake of restricted medications or any drug
             considered likely to interfere with the safe conduct of the trial

          -  Patients unable to comply with the protocol

          -  Previous enrolment in this trial
Clinical trial NCT02757521 (early phase 1, status: terminated)
Conditions: treatment- resistant bipolar disorder, bipolar disorder, bipolar depressive disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: nitrous oxide, placebo
SMILES: [O-][N+]#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study sponsor ended trial due to low recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adults 18-65 years of age

          -  Treatment-resistant bipolar depressive disorder without psychosis and a MADRS baseline
             score of >20. All patients must have history of being on a serum-verified (at time of
             entry into study) mood stabilizer [lithium at 0.5-1.2mEq/L; or valproic acid,
             50-125mcg/ml] for 4 weeks prior to entry into the study and remain on this mood
             stabilizer during the course of the trial. Further, subjects will have failed two
             adequate dose/duration antidepressant courses in their lifetime, including one in the
             current depressive episode (verified by Antidepressant Treatment History Form).

          -  Good command of the English language

        Exclusion Criteria:

          -  Schizophrenia

          -  Schizoaffective disorder

          -  Obsessive-compulsive disorder or panic disorder

          -  Active or recent substance abuse or dependence (in remission at least 1 year prior to
             the study; exception = nicotine use disorders)

          -  A diagnosis of personality disorder that may interfere with the patient's ability to
             improve on nitrous oxide as determined by study investigator

          -  Acute medical illness that may pose subject at risk during nitrous oxide
             administration (neurological disorders or medical disorders including dementia,
             stroke, encephalopathy, Parkinson's Disease, brain tumors, multiple sclerosis, seizure
             disorder, severe cardiac disease, any disease known to affect drug metabolism and
             excretion, i.e. renal or liver disease) per P.I. discretion

          -  Active suicidal intention (inability to contract for safety)

          -  Active psychotic symptoms

          -  Patients with significant pulmonary disease and/or requiring supplemental oxygen

          -  Contraindication against the use of nitrous oxide: pneumothorax; bowel obstruction;
             middle ear occlusion; elevated intracranial pressure; chronic cobalamin and/or folate
             deficiency treated with folic acid or vitamin B12; pregnant patients; breastfeeding
             women; previous administration of NMDA-receptor antagonists (e.g., ketamine); current
             electro-convulsive therapy treatment
Clinical trial NCT02759107 (phase 1, status: completed)
Conditions: healthy, type 2 diabetes mellitus (t2dm)
ICD codes: Z76.3, Z76.2, E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: ly3298176, placebo, dulaglutide
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy participants (Parts A and B) and participants with T2DM diagnosed at least 1
             year before enrollment (Part C)

          -  Have a screening body mass index (BMI) of greater than 18.5 and less than or equal to
             40.0 kilograms per meter squared (kg/m²), inclusive

          -  Participants with T2DM (Part C only): have T2DM controlled with diet and exercise
             alone or are stable on a single oral antidiabetic medication (metformin for at least
             30 days or sulfonylureas). Participants receiving sulfonylureas may participate only
             if this treatment is stopped for at least 6 weeks before dosing with study drug

        Exclusion Criteria:

          -  Have known allergies to LY3298176, glucagon-like peptide (GLP)-1 analogs, or related
             compounds

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the
             opinion of the investigator, increases the risks associated with participating in the
             study

          -  Have a history or presence of pancreatitis (history of chronic pancreatitis or
             idiopathic acute pancreatitis), elevation in serum amylase or lipase (greater than
             2-fold the upper limit of normal [ULN]) or gastrointestinal (GI) disorder (for
             example, relevant esophageal reflux or gall bladder disease) or any GI disease which
             impacts gastric emptying (for example, gastric bypass surgery, pyloric stenosis, with
             the exception of appendectomy) or could be aggravated by glucagon-like peptide-1
             (GLP-1) analogs or dipeptidyl peptidase (DPP)-IV inhibitors

        Participants with T2DM (Part C only)

          -  Have had more than 1 episode of severe hypoglycemia, as defined by the American
             Diabetes Association criteria, within 6 months before entry into the study or has a
             history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms

        All Study Participants (Parts B and C only)

          -  have known allergies to LY3298176, GLP-1 analogs, or related compounds, or
             acetaminophen
Clinical trial NCT02760758 (phase 1, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: cdi-31244, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

        HV and HCV INFECTED SUBJECTS:

          -  Male or female aged ≥ 18 to ≤ 65 years;

          -  Body mass index ≥ 18.5 to ≤ 35.0 kg/m2;

          -  Body weight ≥ 50 kg;

          -  Negative screening for alcohol and drugs of abuse;

          -  Normal results on 12-lead electrocardiogram (ECG);

          -  For females, negative result on a pregnancy test.

        HCV INFECTED SUBJECTS:

          -  HCV treatment-naïve subjects must have not received prior direct acting agent (DAA)
             treatment for hepatitis C infection;

          -  Documented clinical history compatible with chronic hepatitis C;

          -  HCV Genotype 1 by HCV genotyping performed at Screening;

          -  Plasma HCV RNA ≥ 5.0 log10 IU/mL at Screening;

          -  Laboratory evidence of no cirrhosis (negative liver biopsy or fibroscan or FibroTest,
             F2 or lower) within one year prior to study), if these are not available, do a
             FibroTest at screening, which must be F2 or lower.

        Main Exclusion Criteria:

        HV and HCV INFECTED SUBJECTS:

          -  Females who are pregnant or are lactating;

          -  Co-infected with hepatitis B virus (HBV, HBsAg positive) and/or human immunodeficiency
             virus (HIV);

          -  Abuse of alcohol and/or drugs that could interfere with adherence to study
             requirements as judged by the investigator;

          -  Positive screen result for drugs of abuse or alcohol on Day -1. Use of other
             investigational drugs within 60 days of dosing;

          -  Subject with intestinal malabsorption;

          -  Presence of out-of-range cardiac interval on the screening ECG or other clinically
             significant ECG abnormalities;

          -  Serum creatinine > upper limit of normal (ULN);

          -  Any clinically significant medical condition that, in the opinion of the investigator,
             would jeopardize the safety of the subject or impact the validity of the study
             results.

        HEALTHY VOLUNTEERS:

          -  Positive screen for anti-HCV antibody

        HCV INFECTED SUBJECTS:

          -  Clinical (in the opinion of the investigator) or laboratory evidence of cirrhosis;

          -  History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic
             encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal
             hypertension or hepatic insufficiency;

          -  History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC;

          -  Active clinically significant diseases.
Clinical trial NCT02762474 (phase 1/phase 2, status: unknown status)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: nab-paclitaxel group
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Inclusion Criteria:

          1. inoperable locally advanced histologically confirmed esophageal cancer
             (T3N0M0-TxNxM1a（AJCC 2002)

          2. ECOG performance status scale 0-1

          3. at least 1 measurable target lesions

          4. white blood count ≥ 3,500/mm3, absolute neutrophil count ≥ 1,500/mm3, platelet count ≥
             100,000/mm3, hemoglobin count ≥ 90 g/dL, serum bilirubin level < 1.5 of the upper
             limit of normal (ULN) for the institution, aspartate aminotransferase, alanine
             aminotransferase and alkaline phosphatase ≤ 2.5 ULN, serum albumin ≥ 30g/L, serum
             creatinine ≤ 1.5 ULN; and

          5. normal cardiac function with no severe heart disease.

        Exclusion Criteria:

          1. history of esophagectomy

          2. pregnancy or breast feeding

          3. past history of other cancers except for cured non-melanoma skin cancer or cervical
             cancer;

          4. concomitant treatment with other anticancer drugs.
Clinical trial NCT02770521 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: treprostinil, placebo, ly900014, insulin lispro
SMILES: [H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Overtly healthy Japanese

          -  Body mass index (BMI) 18.5 - 25 kilograms per square meter (kg/m²)

          -  Fasting plasma glucose ≥71 milligrams per deciliter (mg/dL) (3.9 millimoles per liter
             [mmol/L]) and <108 mg/dL (6.0 mmol/L) (Part B only)

          -  Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine
             laboratory test results that are acceptable for the study

        Exclusion Criteria:

          -  Are currently enrolled in a clinical trial involving an investigational product or any
             other type of medical research judged not to be scientifically or medically compatible
             with this study

          -  Have participated in a clinical trial involving an investigational product within the
             30 days before study entry.

          -  Have previously completed or withdrawn from this study or any other study
             investigating treprostinil or LY900014, and have previously received the
             investigational product

          -  Have or used to have health problems or laboratory test results or ECG readings that,
             in the opinion of the doctor, could make it unsafe to participate, or could interfere
             with understanding the results of the study